Nefropatia membranosa

Couser WG. Primary Membranous Nephropathy. Clin J Am Soc Nephrol. 2017 Jun 7;12(6):983-997.Texto completo  Resumo

Ronco P, Beck L, Debiec H, et al. Membranous nephropathy. Nat Rev Dis Primers. 2021 Sep 30;7(1):69.Texto completo  Resumo

Kidney Disease: Improving Global Outcomes (KDIGO) Glomerular Diseases Work Group. KDIGO 2021 clinical practice guideline for the management of glomerular diseases. Kidney Int. 2021 Oct;100(4s):S1-S276.Texto completo  Resumo

Peterson JC, Adler S, Burkart JM, et al. Blood pressure control, proteinuria, and the progression of renal disease. The modification of diet in renal disease study. Ann Intern Med. 1995 Nov 15;123(10):754-62. Resumo

von Groote TC, Williams G, Au EH, et al. Immunosuppressive treatment for primary membranous nephropathy in adults with nephrotic syndrome. Cochrane Database Syst Rev. 2021 Nov 15;11(11):CD004293.Texto completo  Resumo

1. Couser WG. Primary Membranous Nephropathy. Clin J Am Soc Nephrol. 2017 Jun 7;12(6):983-997.Texto completo  Resumo

2. Ronco P, Beck L, Debiec H, et al. Membranous nephropathy. Nat Rev Dis Primers. 2021 Sep 30;7(1):69.Texto completo  Resumo

3. Keri KC, Blumenthal S, Kulkarni V, et al. Primary membranous nephropathy: comprehensive review and historical perspective. Postgrad Med J. 2019 Jan;95(1119):23-31.Texto completo  Resumo

4. Haas M, Meehan SM, Karrison TG, et al. Changing etiologies of unexplained adult nephrotic syndrome: a comparison of renal biopsy findings from 1976-1979 and 1995-1997. Am J Kidney Dis. 1997 Nov;30(5):621-31. Resumo

5. Heymann W, Hackel DB, Harwood S, et al. Production of nephrotic syndrome in rats by Freund's adjuvants and rat kidney suspension. Proc Soc Exp Biol Med. 1959;100:660-4.

6. Debiec H, Guigonis V, Mougenot B, et al. Antenatal membranous glomerulonephritis due to anti-neutral endopeptidase antibodies. N Engl J Med. 2002 Jun 27;346(26):2053-60.Texto completo  Resumo

7. Ronco P, Debiec H. Molecular pathomechanisms of membranous nephropathy: from Heymann nephritis to alloimmunization. J Am Soc Nephrol. 2005 May;16(5):1205-13. Resumo

8. Beck LH Jr, Bonegio RG, Lambeau G, et al. M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy. N Engl J Med. 2009;361:11-21.Texto completo  Resumo

9. Qin W, Beck LH Jr, Zeng C, et al. Anti-phospholipase A2 receptor antibody in membranous nephropathy. J Am Soc Nephrol. 2011 Jun;22(6):1137-43. Resumo

10. Iwakura T, Ohashi N, Kato A, et al. Prevalence of enhanced granular expression of thrombospondin type-1 domain-containing 7A in the glomeruli of Japanese patients with idiopathic membranous nephropathy. PLoS One. 2015;10:e0138841.Texto completo  Resumo

11. Reichert LJ, Koene RA, Wetzels JF. Prognostic factors in idiopathic membranous nephropathy. Am J Kidney Dis. 1998;31:1-11. Resumo

12. Mok CC. Membranous nephropathy in systemic lupus erythematosus: a therapeutic enigma. Nat Rev Nephrol. 2009 Apr;5(4):212-20. Resumo

13. Johnson RJ, Couser WG. Hepatitis B infection and renal disease: clinical, immunopathogenetic and therapeutic considerations. Kidney Int. 1990 Feb;37(2):663-76. Resumo

14. Johnson RJ, Gretch DR, Yamabe H, et al. Membranoproliferative glomerulonephritis associated with hepatitis C virus infection. N Engl J Med. 1993 Feb 18;328(7):465-70.Texto completo  Resumo

15. Ronco PM. Paraneoplastic glomerulopathies: new insights into an old entity. Kidney Int. 1999 Jul;56(1):355-77.Texto completo  Resumo

16. Hogan JJ, Markowitz GS, Radhakrishnan J. Drug-induced glomerular disease: immune-mediated injury. Clin J Am Soc Nephrol. 2015 Jul 7;10(7):1300-10.Texto completo  Resumo

17. Stehlé T, Joly D, Vanhille P, et al. Clinicopathological study of glomerular diseases associated with sarcoidosis: a multicenter study. Orphanet J Rare Dis. 2013 Apr 30;8:65.Texto completo  Resumo

18. Ivanyi B. A primer on recurrent and de novo glomerulonephritis in renal allografts. Nat Clin Pract Nephrol. 2008 Aug;4(8):446-57.Texto completo  Resumo

19. Tomas NM, Beck LH Jr, Meyer-Schwesinger C, et al. Thrombospondin type-1 domain-containing 7A in idiopathic membranous nephropathy. N Engl J Med. 2014 Dec 11;371(24):2277-87.Texto completo  Resumo

20. Kidney Disease: Improving Global Outcomes (KDIGO) Glomerular Diseases Work Group. KDIGO 2021 clinical practice guideline for the management of glomerular diseases. Kidney Int. 2021 Oct;100(4s):S1-S276.Texto completo  Resumo

21. Ehrenreich T, Churg J. Pathology of membranous nephropathy. Pathol Annu. 1968;3:145-86.

22. Jefferson JA, Couser WG. Therapy of membranous nephropathy associated with malignancy and secondary causes. Semin Nephrol. 2003 Jul;23(4):400-5.Texto completo  Resumo

23. Giordano M, De Feo P, Lucidi P, et al. Effects of dietary protein restriction on fibrinogen and albumin metabolism in nephrotic patients. Kidney Int. 2001 Jul;60(1):235-42.Texto completo  Resumo

24. Peterson JC, Adler S, Burkart JM, et al. Blood pressure control, proteinuria, and the progression of renal disease. The modification of diet in renal disease study. Ann Intern Med. 1995 Nov 15;123(10):754-62. Resumo

25. von Groote TC, Williams G, Au EH, et al. Immunosuppressive treatment for primary membranous nephropathy in adults with nephrotic syndrome. Cochrane Database Syst Rev. 2021 Nov 15;11(11):CD004293.Texto completo  Resumo

26. Lu W, Gong S, Li J, et al. Efficacy and safety of rituximab in the treatment of membranous nephropathy: a systematic review and meta-analysis. Medicine (Baltimore). 2020 Apr;99(16):e19804.Texto completo  Resumo

27. Dussol B, Morange S, Burtey S, et al. Mycophenolate mofetil monotherapy in membranous nephropathy: a 1-year randomized controlled trial. Am J Kidney Dis. 2008 Oct;52(4):699-705. Resumo

28. Nikolopoulou A, Condon M, Turner-Stokes T, et al. Mycophenolate mofetil and tacrolimus versus tacrolimus alone for the treatment of idiopathic membranous glomerulonephritis: a randomised controlled trial. BMC Nephrol. 2019 Sep 6;20(1):352.Texto completo  Resumo

29. Chan TM, Lin AW, Tang SC, et al. Prospective controlled study on mycophenolate mofetil and prednisolone in the treatment of membranous nephropathy with nephrotic syndrome. Nephrology (Carlton). 2007 Dec;12(6):576-81. Resumo

30. Branten AJ, du Buf-Vereijken PW, Vervloet M, et al. Mycophenolate mofetil in idiopathic membranous nephropathy: a clinical trial with comparison to a historic control group treated with cyclophosphamide. Am J Kidney Dis. 2007 Aug;50(2):248-56. Resumo

31. Scolari F, Alberici F, Mescia F, et al. Therapies for membranous nephropathy: a tale from the old and new millennia. Front Immunol. 2022;13:789713.Texto completo  Resumo

32. Berg AL, Arnadottir M. ACTH-induced improvement in the nephrotic syndrome in patients with a variety of diagnoses. Nephrol Dial Transplant. 2004;19:1305-7.Texto completo

33. Berg AL, Nilsson-Ehle P, Arnadottir M. Beneficial effects of ACTH on the serum lipoprotein profile and glomerular function in patients with membranous nephropathy. Kidney Int. 1999 Oct;56(4):1534-43.Texto completo  Resumo

34. ClinicalTrials.gov. Adrenocorticotropic hormone in membranous nephropathy​. ClinicalTrials.gov identifier: NCT03025828. Aug 2022. [internet publication].Texto completo

35. Ponticelli C, Passerini P, Salvadori M, et al. A randomized pilot trial comparing methylprednisolone plus a cytotoxic agent versus synthetic adrenocorticotropic hormone in idiopathic membranous nephropathy. Am J Kidney Dis. 2006 Feb;47(2):233-40. Resumo